QS

Qsam Biosciences IncOOTC QSAM Stock Report

Last reporting period 30 Sep, 2023

Updated —

Last price

Market cap $B

0

Micro

Exchange

OOTC - OTC

QSAM Stock Analysis

QS

Uncovered

Qsam Biosciences Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0

Dividend yield

Shares outstanding

1.922 B

QSAM Biosciences, Inc. is developing nuclear medicines for the treatment of cancer and related diseases. The Company’s technology, CycloSam (Samarium-153 DOTMP), is a clinical-stage bone targeting radiopharmaceutical developed by IsoTherapeutics Group LLC. Iso Therapeutics Group LLC is also developed a commercial radiopharmaceutical on the market, Quadramet (Samarium-153 EDTMP), which is indicated for pain palliation. CycloSam consists of a combination of the radioactive isotope Samarium-153 and the chelant DOTMP (1,4,7,10-tetraazacyclododecanetetramethylene-phosphonic acid). Its combination delivers a radioactive dose to sites of bone mineral turnover, such as bone cancers and tumors. CycloSam has a physical half-life of approximately 46 hours and emits both medium-energy beta particles, which produce the therapeutic effect and gamma photons that make it possible to locate the anatomical distribution. Its subsidiary is QSAM Therapeutics Inc.

View Section: Eyestock Rating